I. COMMENCED TRADING IN DECEMBER

Company (Symbol)

Date Filed

Date Comm.

Shares/ Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

GenVec Inc. (GNVC)¹

10/5

12/12

4S

$9.50

17.9

J.P. Morgan & Co. UBS Warburg LLC A.G. Edwards & Sons Inc.

$38

$34.1

Harvard Bioscience Inc. (HBIO)²

9/18

12/7

6.25S

$8

24.8

Thomas Weisel Partners LLC Dain Rauscher Wessels ING Barings LLC

$50

$45

Nexia Biotechnologies Inc. (Canada; TSE:NXB)³

10/20

12/19

5S

C$8

N/A

National Bank Financial Inc. RBC Dominion Securities Inc. BMO Nesbitt Burns Inc. HSBC Securities Inc.

C$40 (US$26)

N/A

Specialty Laboratories Inc. (NYSE:SP)⁴

9/12

12/8

5.75S

$16

21

Merrill Lynch & Co. UBS Warburg LLC U.S. Bancorp Piper Jaffray

$92

$83.8

Total: $206M

Number of IPOs in December: 4

Average value of December IPOs: $51.5M

Number of IPOs for 2000: 91

Total raised in IPOs in 2000: $7,212.73M

Average value of IPOs in 2000: $79.26M

Notes:

1 GenVec's underwriters have an overallotment option for 600,000 shares

2 Harvard's underwriters have an overallotment option for 937,500 shares.

3 Nexia went public in Canada. The underwriters have an overallotment option for 750,000 shares.

4 Specialty's underwriters exercised in full the overallotment option for 750,000 shares.

FOLLOW-ON OFFERINGS

Company (Symbol)

Date Filed

Date Comm.

Shares/ Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

Bone Care International Inc. (BCII)⁵

9/12

12/12

2.3S

$16

13.8

Prudential Vector Healthcare U.S. Bancorp Piper Jaffray Robert W. Baird & Co. Inc.

$36.8

$33.9

ICOS Corp. (ICOS)⁶

10/11

12/14

5.175S

$37

51.7

SG Cowen Securities Corp. Bank of America Securities Prudential Vector Healthcare Robertson Stephens Inc. Ragen MacKenzie Inc.

$191.48

$181.4

Neurocrine Biosciences Inc. (NBIX)⁷

10/4

12/6

3S

$30

25.1

Robertson Stephens (co-lead) Salomon Smith Barney (co-lead)

$90

$84.1

North American Scientific Inc. (NASI)⁸

10/19

12/20

2.695S

$17.875

9.7

CIBC World Markets Corp. UBS Warburg LLC Leerink Swann & Co. Inc.

$48.2

$44.8

Oxford Glyco- Sciences plc (UK; LSE:OGS; OGSI)⁹

11/13

12/8

13.37S

£12.75 (US$18.36)

N/A

Lehman Brothers Credit Suisse First Boston Cazenove & Co.

£170.5 (US$254.5)

£137.5 (US$198)

Notes:

5Bone Care's underwriters have an overallotment option for 345,000 shares.

6 ICOS' figures include the full exercise of the underwriters' overallotment option for 675,000 shares.

7 Neurocrine's underwriters have an overallotment option for 450,000 shares

8 North American's offering includes the full exercise of the underwriters' overallotment option for 375,000 shares. The figures do not include 180,000 shares sold by selling stockholders.

9 Oxford offered 9M shares in an international offer and 2.77M under an open offer. The net amount excludes proceeds from the overallotment option The underwriters exercised in full the overallotment option for 1.6M shares.

Total: $620.98M

Number of follow-on offerings in December: 5

Average value of December follow-ons: $124.2M

Number of follow-on offerings in 2000: 67

Total raised in follow-ons in 2000: $16,423.23M

Average value of follow-ons in 2000: $245.12M

II. FILED AND PENDING

Company (Symbol/ Proposed Symbol)*

Date Filed

Shares/ Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

Acadia Pharmaceuticals Inc. (ACAD)¹

12/21

N/A

N/A

N/A

Robertson Stephens Inc. U.S. Bancorp Piper Jaffray

$75

Amersham Pharmacia Biotech (APBiotech; APBI)²

10/3

N/A

N/A

N/A

Morgan Stanley Dean Witter (co-lead) Goldman, Sachs & Co. (co-lead) Chase H&Q Salomon Smith Barney

$100

Athersys Inc.³ (ATHX)

10/12

N/A

N/A

N/A

Credit Suisse First Boston Dain Rauscher Wessels ING Barings LLC

$115

BioMedicines Inc.⁴ (BIOS)

11/3

N/A

N/A

15

UBS Warburg LLC U.S. Bancorp Piper Jaffray Pacific Growth Equities

$57.5

BioTissue Technologies AG⁵ (Germany)

11/29**

1S

EUR27-34

N/A

Landesbank Baden-Wuerttemberg Equinet Securities AG Direkt Anlage Bank AG

EUR27 (US$23)

CombiMatrix Corp. (CLMX)⁶

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead) J.P. Morgan & Co. (co-lead)

$100

diaDexus Inc.⁷ (DDXS)

11/20

N/A

N/A

22.2

Lehman Brothers Inc. CIBC World Markets Corp. Prudential Vector Healthcare Fidelity Capital Markets

$100

DoubleTwist Inc.⁸ (DBLT)

9/1

5S

$13-15

24.2

Lehman Brothers Inc. Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$70

Dynavax Technologies Corp. (DVAX)⁹

12/5

N/A

N/A

N/A

Bank of America Securities LLC UBS Warburg (joint leads)

$75

Exact Corp. (EXAS)¹⁰

10/27

4S

$14-16

18.5

Merrill Lynch & Co. CIBC World Markets Thomas Weisel Partners LLC

$60

Genometrix Inc.¹¹ (GNMX)

3/15

7S

$10-12

30.1

Lehman Brothers (co-lead) Chase H&Q (co-lead) Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$77

Kinetek Pharmaceuticals Inc. (Canada)¹²

10/20

N/A

N/A

N/A

N/A

N/A

NetGenics Inc. (NTGC)¹³

3/13

5.5S

$11-13

23.5

Chase H&Q UBS Warburg LLC

$66

Seattle Genetics Inc. (SGEN)¹⁴

11/20

N/A

N/A

21.7

J.P. Morgan Securities Inc. CIBC World Markets Corp. Bank of America Securities LLC

$75

Third Wave Technologies (TWTI)15

7/31

8.5S

$11-13

44

Lehman Brothers CIBC World Markets Robert W. Baird & Co. Fidelity Capital Markets Dain Rauscher Wessels

$102

Xcyte Therapies Inc. (XCYT)¹⁶

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead) U.S. Bancorp Piper Jaffray (co-lead) Dain Rauscher Inc. First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Aastrom Biosciences Inc. (ASTM)¹⁷

12/7

6.35S

$1.27

33.84

N/A

$8.1

Alexion Pharmaceuticals Inc. (ALXN)¹⁸

10/6

N/A

N/A

N/A

N/A

$300

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)¹⁹

11/16

N/A

N/A

N/A

N/A

C$15 (US$9.6)

Aviron Inc. (AVIR)²⁰

12/18

N/A

N/A

N/A

N/A

$400

Guilford Pharmaceuticals Inc. (GLFD)²¹

11/20

3.5S

N/A

27.4

N/A

$77

Medarex Inc. (MEDX)²²

12/22

N/A

N/A

N/A

N/A

$500

Nexell Therapeutics Inc. (NEXL)²³

12/7

N/A

N/A

N/A

N/A

$25

Transkaryotic Therapies Inc. (TKTX)²⁴

12/13

N/A

N/A

N/A

N/A

$500

Triangle Pharmaceuticals Inc. (VIRS)²⁵

10/23

N/A

N/A

N/A

N/A

$100

Xoma Ltd. (XOMA)²⁶

11/17

10S

$11.25

N/A

N/A

$112.5

III. WITHDRAWN OR POSTPONED

INITIAL OFFERINGS

Company (Symbol/ Proposed Symbol)*

Date Filed/ Date Pulled

Shares/ Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

Cellomics Inc. (CLMX)²⁷

3/3
12/21

6S

$11-13

24.18

Prudential Vector Healthcare ING Barings LLC Dain Rauscher Wessels

$72

FOLLOW-ON OFFERINGS

ImClone Systems Inc. (IMCL)²⁸

11/9
12/22

6S

$57.81

N/A

N/A

$346.86

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed. **Denotes the date the item ran in BioWorld International.

1 Acadia's prospectus gave no further details.

2 Nycomed Amersham said the IPO of its joint venture, APBiotech, will likely occur in February.

3 Athersys' prospectus did not disclose the number of shares to be offered, the price at which they would be offered, or the number of shares outstanding following the offering.

4 BioMedicines' propectus did not disclose the number of shares to be offered or the price at which they would be offered.

5 BioTissue's IPO filing is for Frankfurt's Neuer Markt. In addition to the 1M share certificates offered, there will be a greenshoe of 117,000 shares.

6 CombiMatrix did not disclose the number of shares to be offered or the price at which they would be offered, as well as the number of shares outstanding following the offering.

7 diaDexus' prospectus did not disclose the number of shares to be offered or the price at which they would be offered.

8 The value of DoubleTwist's IPO, $70M, is based on the sale of 5M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 750,000 shares.

9 Dynavax's prospectus gave no further details.

10 Exact plans to offer 3.2M shares in the U.S. and 800,000 internationally. The underwriters have an overallotment option for 600,000 shares. The value of Exact's IPO, $60M, is based on the sale of 4M shares at $15 each, the midpoint of the expected price range.

11 Genometrix's prospectus was amended 4/19, 5/2, 5/22 and 5/23. The estimated value of the IPO, $77M, is based on the sale of 7M shares at $11, the midpoint of the expected price range. The underwriters have an overallotment option for an additional 1.05M shares.

12 Kinetek's proposed IPO is filed in Canada. It was expected to be completed before mid-December. No other details were disclosed.

13 The estimated value of NetGenics' IPO, $66M, is based on the sale of 5.5M shares at an assumed price of $12 per share. The underwriters have an overallotment option for an additional 825,000 shares.

14 Seattle Genetics did not disclose the number of shares it would offer or at what price they would be offered.

15 Third Wave's prospectus was amended 12/13. The underwriters have an overallotment option for 1.275 shares.

16 Xcyte's prospectus gave no further details.

17 The value of Aastrom's offering, $8.1M, is based on the proposed maximum aggregate price of $1.27 per share for 6.35M shares.

18 Alexion filed a shelf registration statement with the SEC to permit the company to offer and sell common stock, debt, or warrants to purchase common stock or debt, up to a value of $300M. No other details were disclosed.

19 AltaRex did not disclose the number of shares to be offered, the price in which they would be offered, or the number of shares to be outstanding following the offering.

20 Aviron filed a shelf registration statement with the SEC to offer up to $400M of any combination of securities.

21 Guilford filed a shelf registration statement with the SEC for 3.5M shares.

22 Medarex filed a shelf registration statement with the SEC to offer up to $500M of any combination of common stock, preferred stock, warrants and debt securities.

23 Nexell filed to sell up to $25M of common stock. No other details were disclosed.

24 Transkaryotic Therapies filed with the SEC a shelf registration statement for the sale of up to $500M of securities.

25 Triangle filed a shelf registration statement for the sale of up to $100M worth of common stock. No other details were disclosed.

26 Xoma filed a shelf registration statement with the SEC for 10M shares. The value, $112.5M, is based on the closing price on 11/16.

27 Cellomics postponed its IPO until the first quarter of 2001

28 ImClone withdrew its shelf registration statement.